2024-07-19 11:00:37
BioInvent, known for its innovative cancer immunotherapies, is expanding its partnership with MSD to test BI-1607 in combination with ipilimumab and KEYTRUDA in a phase II trial for metastatic melanoma. The phase II study aims to enhance the efficacy of these existing treatments while reducing toxicity, potentially offering a more tolerable and effective treatment regimen.
Read the article at biostock.se:
BioInvent and MSD to evaluate new metastatic melanoma treatment (https://www.biostock.se/en/2024/07/bioinvent-and-msd-expand-partnership-to-evaluate-new-metastatic-melanoma-treatment/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/